Pfizer has reported positive results from its Phase II trial evaluating the 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants.
The trial compared 25vPnC to PREVNAR 20 (PCV20) over a four-dose schedule at two, four, six, and 12-15 months of age, focusing on tolerability, immunogenicity, and safety.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Key Phase II data shared at the International Society of Pneumonia & Pneumococcal Diseases meeting in Denmark showed that geometric mean titers for serotype 3 were 8.8-fold higher with 25vPnC compared to PREVNAR 20, one month after the third dose.
After the fourth dose, the titers were approximately 15-fold higher with 25vPnC than PCV20.
The vaccine candidate is projected to provide coverage for up to 90% of disease-causing serotypes in children under five years, with around 15% attributed to serotype 3.
Pfizer senior vice-president and chief vaccines officer Annaliesa Anderson said: “For more than 25 years, our vaccines have helped protect children from pneumococcal disease, yet significant disease burden remains.
“These Phase II results reinforce our confidence in a next-generation vaccine designed to expand protection across serotypes while improving responses to key residual disease drivers such as serotype 3.”
The randomised Phase II study in healthy infants began enrolment in July 2024. Participants received either 25vPnC or PCV20, with safety, tolerability, and immunogenicity assessed at regular intervals post-vaccination.
Local reactions included redness, swelling, or pain at the injection site, consistent with current vaccines.
Phase III studies commenced this month to further evaluate the safety, tolerability, and immunogenicity of 25vPnC versus PCV20 in up to 2,400 healthy children.
The vaccine expands coverage by adding five new serotypes to the current 20-valent vaccine. In the adult segment, Pfizer intends to introduce a fifth-generation vaccine with 35 serotypes, entering clinical development later this year.
In March 2026, Pfizer’s oral cyclin-dependent kinase 4 (CDK4) inhibitor, atirmociclib, met the primary endpoint in a Phase II trial as a second-line treatment for breast cancer.
